Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847296 | 0.91 | P2RY12 (0.39) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL27631461 | 0.90 | MEN1 (0.42) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL4853934 | 0.90 | HTT (0.43) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL4858255 | 0.88 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4855096 | 0.86 | P2RY12 (0.41) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL4854020 | 0.86 | ALDH1A1 (0.43) | MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4848396 | 0.84 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9AGAA | |
| SCHEMBL13294998 | 0.84 | KDM4E (0.44) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL14195164 | 0.83 | MAPT (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4848292 | 0.83 | MAPT (0.40) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1656376-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005021546-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | MIF, MSR1, SLC11A2 | MEN1 1559/4885KMT2A 4090/4885NPC1 156/4885 |
| US-20050124604-A1 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | MIF, MSR1, SLC11A2 | MEN1 1559/4885KMT2A 4090/4885NPC1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.